Marizyme is a small medical technology company focused on commercializing DuraGraft, a single-use solution used to preserve saphenous vein grafts during coronary artery bypass graft (CABG) surgery. The clinical problem DuraGraft addresses is vein graft failure — roughly 30% of grafts fail within the first year after surgery — by reducing oxidative damage and preserving the structural integrity of harvested veins. DuraGraft is the only FDA-cleared and CE-marked product approved specifically as a vascular conduit storage and flushing solution for CABG, competing indirectly against the standard of care, which uses basic saline or heparinized blood with no cytoprotective benefit. Marizyme sells single-use units per procedure, with revenue driven by CABG procedure volume and penetration among cardiac surgery programs. Internationally, Marizyme sells through distributors in Europe and Asia. In the U.S., where Marizyme received FDA clearance in October 2023, Marizyme plans to sell directly to hospital networks using a small direct sales force. Marizyme does not manufacture DuraGraft itself, relying on contract manufacturers and third-party distributors, keeping fixed costs low but creating supply chain dependency. Beyond DuraGraft, Marizyme has early-stage pipeline assets in fat grafting and kidney disease diagnostics, but both are effectively paused due to capital constraints. With only 11 full-time employees, Marizyme's near-term performance depends heavily on the pace of DuraGraft adoption and its ability to raise additional capital to fund commercialization.